Relapsed/Refractory Multiple Myeloma: Interpreting MonumenTAL-3 Efficacy and Safety Findings

Description - Dr. Ajai Chari and Dr. Rahul Banerjee review the key efficacy and safety findings from the phase 3 MonumenTAL-3 study in relapsed/refractory multiple myeloma (RRMM). The faculty discuss the significant progression-free survival benefit observed with talquetamab-based combinations compared with daratumumab, pomalidomide, and dexamethasone, highlighting the magnitude of benefit achieved across both talquetamab-containing treatment arms. The conversation explores the emerging overall survival data and considers the implications of introducing T-cell–redirecting therapies earlier in the disease course. Dr. Banerjee and Dr. Chari also examine practical differences between the talquetamab plus daratumumab and talquetamab plus daratumumab and pomalidomide regimens, including efficacy considerations and treatment-related toxicities. A substantial portion of the discussion focuses on adverse event management, including cytokine release syndrome, taste alterations, skin and nail changes, weight loss, and infection risk. The faculty highlight the unique safety profile associated with GPRC5D-directed therapy and discuss how dosing modifications, supportive care strategies, and growing clinical experience may help optimize treatment outcomes for patients with RRMM.